Short Interest in DarioHealth Corp. (NASDAQ:DRIO) Drops By 17.3%

DarioHealth Corp. (NASDAQ:DRIO) was the target of a large decrease in short interest in the month of January. As of January 30th, there was short interest totaling 64,677 shares, a decrease of 17.3% from the January 15th total of 78,193 shares. Approximately 1.0% of the company’s shares are sold short. Based on an average daily trading volume, of 7,270 shares, the short-interest ratio is presently 8.9 days. Based on an average daily trading volume, of 7,270 shares, the short-interest ratio is presently 8.9 days. Approximately 1.0% of the company’s shares are sold short.

Institutional Investors Weigh In On DarioHealth

Several institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd grew its stake in shares of DarioHealth by 229.0% in the second quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after acquiring an additional 43,513 shares during the period. Geode Capital Management LLC boosted its holdings in DarioHealth by 167.9% in the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after purchasing an additional 31,063 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in DarioHealth in the 4th quarter worth approximately $35,000. Institutional investors own 33.39% of the company’s stock.

DarioHealth Stock Down 2.1%

Shares of DRIO traded down $0.25 during trading hours on Tuesday, hitting $11.47. The company had a trading volume of 4,993 shares, compared to its average volume of 16,189. The stock has a market capitalization of $77.54 million, a price-to-earnings ratio of -1.03 and a beta of 1.16. The firm has a fifty day moving average price of $11.40 and a 200-day moving average price of $11.68. DarioHealth has a 52-week low of $5.93 and a 52-week high of $17.74. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.02 and a current ratio of 4.55.

Wall Street Analysts Forecast Growth

DRIO has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of DarioHealth in a research note on Monday, December 29th. Wall Street Zen lowered DarioHealth from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th. Stifel Nicolaus set a $16.00 price objective on shares of DarioHealth in a report on Friday, November 14th. Finally, TD Cowen reaffirmed a “hold” rating on shares of DarioHealth in a research report on Friday, November 14th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, DarioHealth has an average rating of “Hold” and an average target price of $38.00.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.